UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 19, 2013 (February 14, 2013)
Merck & Co., Inc.
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
(State or Other Jurisdiction of Incorporation)
|
1-6571 |
|
22-1918501 |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
One Merck Drive, PO Box 100, Whitehouse Station, NJ |
|
08889-0100 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code (908) 423-1000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by the Registrant on February 14, 2013, entitled “Merck Resolves Securities Class-Action Lawsuits Related to the ENHANCE Trial,” attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. This supplemental information consists of financial tables which were originally furnished by the Registrant as part of Exhibits 99.1 and 99.2 to a Form 8-K dated February 1, 2013. Certain of these tables have been amended where appropriate to reflect the settlement of the litigation referred to in Exhibit 99.1.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit 99.1 |
|
Press release issued February 14, 2013 entitled “Merck Resolves Securities Class-Action Lawsuits Related to the ENHANCE Trial” |
|
|
|
|
|
Exhibit 99.2 |
|
Certain supplemental information not included in the press release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Merck & Co., Inc. | |
|
|
| |
|
|
| |
|
Date: February 19, 2013 |
By: |
/s/ Katie E. Fedosz |
|
|
|
KATIE E. FEDOSZ |
|
|
|
Senior Assistant Secretary |